Imatinib Mesylate

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Gastrointestinal Stromal Tumors

Conditions

Gastrointestinal Stromal Tumors

Trial Timeline

Jul 1, 2004 → —

NCT ID

NCT00171977

About Imatinib Mesylate

Imatinib Mesylate is a approved stage product being developed by Novartis for Gastrointestinal Stromal Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00171977. Target conditions include Gastrointestinal Stromal Tumors.

What happened to similar drugs?

5 of 20 similar drugs in Gastrointestinal Stromal Tumors were approved

Approved (5) Terminated (4) Active (11)

🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3

✅Remimazolam TosilateJiangsu Hengrui MedicineApproved

❌Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3

🔄Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3

🔄Durvalumab + FLOT chemotherapyAstraZenecaPhase 3

🔄EsomeprazoleAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01742299	Approved	Active	Mar 26, 2013	Apr 21, 2033	GIST and CML
NCT00867113	Phase 2	Completed	Jul 22, 2009	Dec 20, 2016	Gastrointestinal Stromal Tumor (GIST)
NCT00732784	Phase 1	Completed	Nov 1, 2008	Dec 1, 2012	Healthy
NCT01172548	Phase 2	Completed	Aug 1, 2008	Mar 1, 2014	Gastrointestinal Stromal Tumors
NCT01483014	Phase 2	Completed	Jun 1, 2008	Jan 1, 2012	Gastrointestinal Stromal Tumors
NCT00684411	Phase 2	Completed	Jun 1, 2008	Oct 1, 2013	T Cell Non-Hodgkin Lymphoma
NCT01545427	Phase 2	Terminated	Apr 1, 2008	Dec 1, 2008	Scleroderma
NCT00479934	Phase 2	Completed	Dec 1, 2007	Dec 1, 2010	Scleroderma, Localized
NCT00677092	Phase 2	Completed	Dec 1, 2007	Jul 1, 2009	Nephrogenic Systemic Fibrosis
NCT00555581	Phase 2	Completed	Aug 1, 2007	Dec 1, 2011	Systemic Sclerosis
NCT00510354	Approved	Completed	Oct 1, 2006	Nov 1, 2012	Progressive Gastrointestinal Stromal Tumor
NCT00427583	Phase 2/3	Terminated	May 1, 2006	—	Malignant Peripheral Nerve Sheath Tumors
NCT00124748	Phase 3	Terminated	Jun 1, 2005	Nov 1, 2010	Leukemia, Myeloid, Chronic Phase
NCT00171899	Approved	Completed	Apr 1, 2005	Jun 1, 2007	Chronic Myelogenous Leukemia
NCT00171912	Phase 2	Completed	Sep 1, 2004	Jan 1, 2012	Hypereosinophilic Syndrome
NCT00171977	Approved	Completed	Jul 1, 2004	—	Gastrointestinal Stromal Tumors
NCT00171938	Phase 2	Terminated	Apr 1, 2004	Jun 1, 2006	Glioblastoma
NCT00154349	Phase 2	Completed	Oct 1, 2003	Feb 1, 2007	Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
NCT00237172	Phase 2	Completed	Sep 1, 2002	—	Gastrointestinal Stromal Tumors
NCT00171860	Phase 2	Terminated	Sep 1, 2002	—	Hypereosinophilic Syndrome

Competing Products

20 competing products in Gastrointestinal Stromal Tumors

See all competitors

Product	Company	Stage	Hype Score
Raludotatug Deruxtecan (R-DXd)	Daiichi Sankyo	Phase 2	39
Patritumab deruxtecan	Daiichi Sankyo	Phase 1/2	39
DS-6157a	Daiichi Sankyo	Phase 1	21
DS-8201a + Physician's Choice	Daiichi Sankyo	Phase 2	35
Naldemedine + Placebo	Shionogi	Phase 2	27
Gemcitabine	Eli Lilly	Phase 1/2	32
Olaratumab	Eli Lilly	Phase 2	27
pemetrexed + cisplatin	Eli Lilly	Phase 2	35
cetuximab	Eli Lilly	Phase 2	35
BBI503	Sumitomo Pharma	Phase 2	27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + Regorafenib	Sumitomo Pharma	Phase 1/2	32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)	Johnson & Johnson	Phase 3	40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)	Johnson & Johnson	Phase 2	35
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	43
Famitinib capsules + Sunitinib Capsules	Jiangsu Hengrui Medicine	Phase 3	32
Famitinib	Jiangsu Hengrui Medicine	Phase 2	31
Esomeprazole IV + Omeprazole IV	AstraZeneca	Phase 3	40
Durvalumab + FLOT chemotherapy	AstraZeneca	Phase 3	44
Esomeprazole	AstraZeneca	Phase 3	40
AZD2171	AstraZeneca	Phase 2	35